Dynamic Technology Lab Private Ltd Takes $912,000 Position in Agilent Technologies, Inc. $A

Key Points

• Dynamic Technology Lab Private Ltd acquired a new position in Agilent Technologies, purchasing 7,794 shares valued at approximately $912,000.
• Agilent Technologies reported quarterly earnings of $1.37 per share, meeting estimates, and a revenue of $1.74 billion, surpassing analysts' expectations.
• Several hedge funds have significantly increased their holdings in Agilent, with Whipplewood Advisors LLC raising its stake by 286.2% during the first quarter.

Dynamic Technology Lab Private Ltd bought a new position in Agilent Technologies, Inc. (NYSE:A - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 7,794 shares of the medical research company's stock, valued at approximately $912,000.

Several other hedge funds have also bought and sold shares of A. Whipplewood Advisors LLC raised its stake in shares of Agilent Technologies by 286.2% in the first quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company's stock worth $29,000 after buying an additional 186 shares during the period. Sunbelt Securities Inc. increased its holdings in Agilent Technologies by 640.0% in the 4th quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company's stock worth $30,000 after acquiring an additional 192 shares in the last quarter. Stone House Investment Management LLC bought a new stake in Agilent Technologies during the 1st quarter worth approximately $30,000. Opal Wealth Advisors LLC bought a new position in shares of Agilent Technologies in the first quarter worth approximately $31,000. Finally, Wood Tarver Financial Group LLC bought a new position in shares of Agilent Technologies in the fourth quarter worth approximately $34,000.

Agilent Technologies Trading Down 0.5%

Shares of A stock opened at $128.13 on Tuesday. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $36.32 billion, a price-to-earnings ratio of 30.08, a price-to-earnings-growth ratio of 4.00 and a beta of 1.24. Agilent Technologies, Inc. has a 12-month low of $96.43 and a 12-month high of $153.84. The stock's 50-day moving average price is $119.42 and its 200-day moving average price is $116.00.

Agilent Technologies (NYSE:A - Get Free Report) last released its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, meeting the consensus estimate of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.67 billion. During the same quarter last year, the business posted $1.32 EPS. The firm's revenue for the quarter was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities research analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on A. Wells Fargo & Company lifted their target price on shares of Agilent Technologies from $135.00 to $140.00 and gave the company an "overweight" rating in a research note on Thursday, August 28th. Evercore ISI decreased their price target on Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating on the stock in a report on Thursday, August 28th. Leerink Partners upped their price objective on Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research note on Friday, May 30th. JPMorgan Chase & Co. decreased their target price on Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating on the stock in a research note on Thursday, May 29th. Finally, TD Cowen boosted their price target on Agilent Technologies to $150.00 and gave the stock a "buy" rating in a report on Thursday, May 29th. Six equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $139.25.

Insiders Place Their Bets

In related news, CEO Padraig Mcdonnell sold 1,508 shares of the company's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the sale, the chief executive officer owned 37,448 shares of the company's stock, valued at $4,397,893.12. This represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.